performed a randomized phase II trial compared 1 month versus 1 year of adjuvant high-dose interferon α-2b (HD-IFN) in high-risk (stages IIb–IIIc) acral melanoma patients. Here, IFNA1 is linked to acral lentiginous melanoma.